• Universal MRD solution unbounded to baseline sample availability
• Personalized MRD detection with ability to capture new mutations
• Designed to monitor cancer treatment response or detect cancer recurrence
• Adopted by leading biopharmas in global clinical trials
PredicineALERT is a personalized assay based on the unique alterations of each tumor. Baseline can be assessed using patient’s plasma, urine or tissue. With our advanced technology and tissue-agnostic approach, monitoring the recurrence or progression of cancer can be achieved with a simple blood draw in a non-invasive way.
MRD detection with PredicineALERT™ is different from traditional uses of ctDNA because it uses an integrated approach that analyzes variants, methylation, and chromosomal abnormalities simultaneously, making it more sensitive and personalized than mutation or methylation tests alone.
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.